VBValery V. Benberin

Valery V. Benberin

*This is an algorithmically generated author record based on publicly available information.

Valery V. Benberin has a total of 66 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Possibilities of Photodynamic Therapy in the Treatment of Multiple Cylindroma of the Scalp: The Clinical Case Study

    by Nasrulla Shanazarov, Valery Benberin, Sergey Zinchenko, Fatima Nalgieva, Niyaz Muratov, Bakitzhan Isahanova, Tokhirzhan Tashpulatov

    This article presents a clinical observation of successful treatment of a patient with multiple cylindroma of the scalp and trunk using photodynamic therapy (PDT) after radiotherapy. The first masses were found in 2008, at the same time they were surgically removed. There has been a progression of the process since 2019 - multiple masses on the scalp and trunk. There was another visit to doctors. After verification of diagnosis radiation therapy was received. However, soon after the treatment, the appearance of new and growth of existing foci has been noted. A multistage PDT with good clinical and cosmetic effect was carried out at Medical Centre Hospital of President’s Affairs Administration of the Republic of Kazakhstan.


  • Open Access

    MODERN CONCEPTS OF THE MOLECULAR GENETIC MARKERS OF PROSTATE CANCER

    by V. V. Benberin, N. A. Shanazarov, M. E. Tuleutaev, N. K. Seydalin, A. Zh. Davranov, A. M. Zhumakayeva, T. M. Muratov, B. G. Kasymov

    Purpose of the study: to present up-to-date data on molecular genetic studies aimed to identify the risks of developing prostate cancer in representatives of various ethnic groups. Material and Methods. Literary sources were searched in databases such as PubMed, Medline, Google Scholar. We had analyzed 60 sources on the risks of developing prostate cancer. The epidemiological data on the prostate cancer incidence and risk factors depending on age characteristics, hormonal status and hereditary predisposition were shown. Results. The pathogenetic features of prostate cancer depending on ethnicity were described. The paper presents data from both European and Asian ethnic groups. In a number of studies, significant genetic differences in single nucleotide polymorphisms associated with the development of prostate cancer were identified. Conclusion. Research in the field of determining the risks of developing prostate cancer becomes more and more relevant due to the emergence of new molecular genetic markers, as well as the influence of various ethnic characteristics. Nevertheless, many questions of modern diagnosis of prostate cancer are still open, therefore, research in this area remains promising.


  • COMPLEX ASSESSMENT OF COMPUTED TOMOGRAPHY OF THE LUNGS AND CLINICAL DATA IN COVID-19 PATIENTS, HOSPITALIZED IN THE CLINIC IN NUR-SULTAN

    by R.I. Rakhimzhanova, Amu, D. Pavalkis, V.V. Benberin, T.B. Dautov, Zh.S. Abdrakhmanova, E.S. Yelshibayeva

    The ambiguity of the X-ray picture and clinic in patients with coronavirus infection (CVI) was the reason for this analysis in order to avoid diagnostic errors and to achieve the effect of the treatment. Conducted a comparative description of three clinical cases of patients with coronavirus infection COVID-19. All three patients differed in different parameters of SARS Co-2 PCR. In the first two patients who underwent CT on the 7th and 10th days from the onset of the disease on control CT after treatment, a regressive positive dynamics was observed; in the third patient, after an early CT scan on the second day of illness and on the next CT scan performed on the 10th day after the appearance of the clinic and a positive PCR test, progression of signs of viral pneumonia was observed with an increase in the affected area. Thus, the earlier CT was performed, the less pronounced the changes in the CT picture (the lesion volume is up to 5% or no changes are detected). When performing CT scan, patients with a long-term clinic (7-10 days from the onset of the disease) showed a characteristic picture of lung damage - up to 25-30%. The analysis of CT scans performed in the described clinical cases at different times from the onset of the disease, regardless of the results of PCR, confirms the need for CT scans 5-7 days after the first clinical signs appear. Also, as a result of our work, we once again received confirmation from numerous studies conducted in the world on the absence of a correlation between SARS Co-2 PCR and CT data.

  • INFLUENCE ON HOMEOSTASIS AS THE CRITERION FOR SELECTING SINGLE NUCLEOTIDE POLYMORPHISMS FOR THE STUDY OF METABOLIC SYNDROM IN THE KAZAKH POPULATION

    by V.V. Benberin, T.A. Voshchenkova, A.A. Nagymtayeva, A.S. Sibagatova, K.M. Akhmetova, A.N. Makhmutova

    Metabolic syndrome (MS) is increasingly cited as the world's leading health risk. The sequence of events toward multimorbidity in most cases passes through MS. According to the research, MS heritability ranges from 23 to 27% in Europeans, and 51 to 60% in Asians. The purpose of the review: to form a strategy for the selection of single nucleotide polymorphisms (SNPs) for the study of MS in the Kazakh population based on the effect of SNPs on homeostasis indicators The stable symptom complex of MS is a complicated dynamic system of successive accumulations of dysmetabolic disorders of homeostasis. This system starts the development of subsequent age-associated diseases), such as cardiometabolic, neurodegenerative, and malignant neoplasms. The system for selecting SNPs for the MS study, proposed on the basis of the concept of homeostasis dysfunction, assumes, in conditions of limited resources, to see the greatest level of their influence within the conditional framework of three genetic models of homeostasis dysregulation: insulin resistance , oxidative stress, and chronic inflammation. This approach is fundamentally different from the traditional approach involving candidate genes. It is expected that scientific research in this direction will contribute not only to the understanding of general biological processes, but also to the targeted search for genetic determinants and for new opportunities for personalized interventions.

  • Open Access

    THE CLINICAL EFFECT OF PROBIOTIC-CONTAINING PRODUCT ON HEALTH INDICATORS AMONG A POPULATION OF CENTRAL ASIA

    by Kushugulova A.R., Forslund S.K., Kozhakhmetov S.S., Kairov U.E., Molkenov A.B., Sergazy Sh.D., Saduakhassova S.A., Urazbayeva G.S., Beysembayeva S.CH., Karabaeva R.ZH., et al.

    Introduction. The main goal is to test the efficacy of a synbiotic product which consists of the selected probiotic strains (Lactobacillus plantarum, Lactobacillus fermentum, Lactobacillus acidophilus, Bifidobacterium longum, Bifidobacterium bifidum), inulin, pectin, and fish collagen in adults diagnosed with metabolic syndrome. Materials and methods. This double-blind placebo-controlled trial was conducted among 180 participants aged 25 to 75 years. Subjects with and without metabolic syndrome were randomly assigned to receive synbiotic or placebo daily for three months. 134 of 180 participants completed the study. Results. Compared with the placebo group, the synbiotic group had significantly decreased total cholesterol (TC) from 5.160.95 to 4.860.86 mmol/L, due to lowering the levels of LDL and triglyceride (p 0.0005). The present findings suggest positive influence of the tested synbiotic on controlling excess weight and in treating some metabolic disorders in adults. Conclusion We conclude that the presented synbiotic formulation here has potential within efforts to reduce the risk and progression of the metabolic syndrome. This trial suggests beneficial effects of a synbiotic supplement for controlling excess weight, as well as the progression of some metabolic disorders, as determined from circulating levels of risk factor biomarkers among adults. Введение. Основная цель - проверить эффективность синбиотического продукта, который состоит из отобранных пробиотических штаммов (Lactobacillus plantarum, Lactobacillus fermentum, Lactobacillus acidophilus, Bifidobacterium longum, Bifidobacterium bifidum), инулин, пектин и рыбный коллаген среди взрослого населения с диагностированным метаболическим синдромом. Материалы и методы. Это двойное слепое плацебо-контролируемое исследование было проведено среди 180 участников в возрасте от 25 до 75 лет. Субъекты с метаболическим синдромом и без были случайным образом распределены на прием синбиотика или плацебо. Продукт принимали ежедневно в течение трех месяцев. 134 из 180 участников завершили исследование. Результаты. По сравнению с плацебо, в группе, принимавшей синбиотики, общий уровень холестерина (ТС) значительно снизился с 5,16 0,95 до 4,86 0,86 ммоль / л за счет снижения уровня ЛПНП и триглицеридов (р 0,0005). Полученные данные свидетельствуют о положительном влиянии тестируемого синбиотика на контроль избыточного веса и лечение некоторых нарушений обмена веществ у взрослых. Заключение. Мы пришли к выводу, что исследуемый синбиотик имеет потенциал по снижению риска и прогрессирования метаболического синдрома. Настоящее исследование определило позитивный эффект применениясинбиотика в качестве вспомогательной терапии для контроля избыточного веса, а также прогрессирование некоторых метаболических нарушений. Крспе. Негзг масат - тадалан пробиотикалы штаммдардан (Lactobacillus plantarum, Lactobacillus fermentum, Lactobacillus acidophilus, Bifidobacterium longum, Bifidobacterium bifidum), инулин, пектин жне балы коллагеннен тратын синбиотикалы нмн тимдлгн метаболикалы синдром диагнозы ойылан ересек трындар арасында тексеру. Материалдар мен дстер. Бл осарлы жасырын плацебо-баыланатын зерттеу 25-тен 75 жаса дейнг 180 атысушыларды арасында жргзлд. Метаболикалы синдромы бар жне жо субъектлер синбиотик немесе плацебо абылдауа кездейсо блнген. нм кн сайын ш ай шнде абылданды. 180 атысушыны 134- зерттеуд аятады. Нтижелер. Плацебомен салыстыранда, синбиотиктерд абылдаан топта ТТЛП мен шацилглицеридтер дегейн тмендеу есебнен холестеринн (ЖХ) жалпы дегей 5,16 0,95-тен 4,86 0,86 ммоль/л-ге дейн (р 0,0005) айтарлытай тмендед. Алынан млметтер сыналатын синбиотикт ересектерде арты салматы баылауа жне зат алмасуды кейбр бзылыстарын емдеуге о серн длелдейд. орытынды. Бз, зерттелетн синбиотикт метаболикалы синдромны атерн жне деун азайту леует бар деген орытындыа келдк. Осы зерттеу арты салматы баылауда, сондай-а кейбр метаболикалы бзылыстарды деунде осымша терапия ретнде синбиотикт олдануды о серн анытады.

  • CLINICAL IMPORTANCE OF DEFINITION OF SINGLE NUCLEOTIC POLYMORPHISMS IN PATIENTS WITH BREAST CANCER (LITERATURE REVIEW)

    by V. V. Benberin, N. A. Shanazarov, N. K. Seidalin, N. Y. Lisovska, T. A. Vochshenkova, G. A. Yermakhanova

  • PHOTODYNAMIC THERAPY IN THE TREATMENT OF PATIENTS WITH PURULENT WOUNDS

    by V. V. Benberin, N. A. Shanazarov, R. I. Rakhimzhanova, R. R. Akhmetzakirov, D. E. Turzhanova

  • POLYMORPHISMS OF SOME GENES, ASSOCIATED WITH HYPERTENSION: A REVIEW OF RELEVANT PUBLICATIONS

    by V. V. Benberin, G. A. Yermakhanova, N. A. Shanazarov, T. A. Vochshenkova, N. K. Seidalin, N. Y. Lisovska

  • MARE’S MILK: THERAPEUTIC AND DIETARY PROPERTIES

    by B. Bimbetov, Professor. Rse " Md, A. Zhangabylov, S. Aitbaeva, V. Benberin, H. Zollmann, A. Musaev, M. Rakhimzhanova, G. Esnazarova, A. Bakytzhanuly, et al.